# Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-stifel-healthcare-conference-4773aab0
Ticker: ABOS
Company: Acumen Pharmaceuticals
Source: Acumen Pharmaceuticals
Published: 2025-11-04 21:00 EST
## Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel...

## Article Body
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at 4:40 p.m. ET.

The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE ® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com .

Investors: Alex Braun abraun@acumenpharm.com

Media: AcumenPR@westwicke.com
## Recent Company News
- 2026-07-15 11:30 EST — [Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-e-12dd8779) — Source: Acumen Pharmaceuticals
- 2026-07-07 11:30 EST — [Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-95eca401) — Source: Acumen Pharmaceuticals
- 2026-06-16 11:30 EST — [Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-announces-nomination-of-two-enhanced-brain-delivery-ebd-d-d74b8122) — Source: Acumen Pharmaceuticals
- 2026-05-12 11:00 EST — [Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-ba885971) — Source: Acumen Pharmaceuticals
- 2026-05-07 20:00 EST — [Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2026-hea-e907fb55) — Source: Acumen Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)